Tenax Therapeutics, Inc. (NASDAQ:TENX) Short Interest Update

Tenax Therapeutics, Inc. (NASDAQ:TENX) was the recipient of a large growth in short interest in June. As of June 15th, there was short interest totalling 9,900 shares, a growth of 54.7% from the May 31st total of 6,400 shares. Based on an average daily trading volume, of 32,700 shares, the short-interest ratio is presently 0.3 days. Currently, 0.5% of the company’s shares are sold short.

Analyst Ratings Changes

Separately, StockNews.com started coverage on Tenax Therapeutics in a report on Sunday. They set a “sell” rating on the stock.

Tenax Therapeutics Price Performance

Shares of TENX traded up $0.03 during trading hours on Friday, reaching $3.01. The stock had a trading volume of 4,161 shares, compared to its average volume of 21,288. Tenax Therapeutics has a 12 month low of $2.77 and a 12 month high of $61.20. The firm has a 50-day simple moving average of $3.45 and a 200 day simple moving average of $7.30.

Tenax Therapeutics (NASDAQ:TENX) last issued its earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($3.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.72). Sell-side analysts anticipate that Tenax Therapeutics will post -7.96 earnings per share for the current fiscal year.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.